NSE: WOCKPHARMA | BSE: 532300 | ASM

Mid-range Performer

Download real time

1904.30 53.70 (2.90%)

75.24% Gain from 52W Low

1.3M NSE+BSE Volume

NSE 02 Sep, 2026 3:31 PM (IST)

30,943.4

Market Cap

High in industry

-

Beta 1Year

Average volatility

Wockhardt Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for WOCKPHARMA, BSE:532300 Wockhardt Ltd.

Search Inside the pdf :

12 Jun 2026

1904.30

2.90%

Turnaround? Or execution still under scrutiny

buy

Not Rated: Wockhardt Ltd.

Deven Choksey

Wockhardt has transformed into an innovation-led pharmaceutical company with a strong pipeline of novel antibiotics, highlighted by the USFDA approval of Zaynich.

Wockhardt has gained 39.83% in the last 6 Months

08 Jul 2025

1904.30

2.90%

Axis Punch:Wockhardt

buy

Buy: Wockhardt Ltd.

Axis Direct

We recommend a BUY rating on the stock, with a target price of Rs 1,870/share reflecting 10% upside potential from the CMP.

Number of FII/FPI investors increased from 180 to 198 in Jun 2026 qtr.

31 Jan 2018

1904.30

2.90%

Wockhardt Ltd Q3FY18 results comment

buy

Results Update: Wockhardt Ltd.

HDFC Securities

Wockhardt Ltd Q3FY18 results comment Revenue decreased by 1.66% to Rs. 1005.3 Cr in Q3FY18 when compared to the previous quarter

Number of FII/FPI investors increased from 180 to 198 in Jun 2026 qtr.

23 May 2017

1904.30

2.90%

Wockhardt Ltd Q4FY17 results comment

buy

Results Update: Wockhardt Ltd.

HDFC Securities

Revenue fell by 13.26% to Rs. 863.53 Cr in Q4FY17 when compared to the previous quarter.

Wockhardt Ltd. is trading below its 30 day SMA of 1912.8

31 Jan 2017

1904.30

2.90%

Wockhardt Ltd Q3FY17 results comment

buy

Results Update: Wockhardt Ltd.

HDFC Securities

Revenue fell by 6.49% to Rs. 995.56 Cr in Q3FY17 when compared to the previous quarter. Also, it decreased by 7.35% when compared with Q3FY16.

Number of FII/FPI investors increased from 180 to 198 in Jun 2026 qtr.

Is Wockhardt Ltd. worth buying?

465 Votes:

Buy 73.55%

Sell 16.99%

Hold 9.46%

RESEARCH REPORTS

Not Rated SEE REPORTS >

Buy SEE REPORTS >